Physician profile
Robert B Strimling
NPI 1699746768
$9,642.43
in general payments reported to CMS, 2019-2025
42 companies · $168 in 2025
The $168 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,687 · 2020: $1,128 · 2021: $794 · 2022: $1,556 · 2023: $2,027 · 2024: $1,282 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,797 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $512 · Education: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,797.35 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $512.45 |
| Education | $166.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,814.77 | 2019-2025 | Skyrizi, Rinvoq |
| Merz North America, INC. | $1,251.24 | 2019-2023 | Xeomin |
| Pfizer INC. | $831.06 | 2019-2025 | |
| Janssen Biotech, INC. | $606.64 | 2019-2024 | Tremfya |
| Genzyme Corporation | $433.52 | 2019-2025 | |
| Dermavant Sciences, INC. | $406.84 | 2022-2024 | Vtama |
| Janssen Scientific Affairs, LLC | $260.92 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $253.67 | 2022-2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $250.07 | 2019-2022 | |
| Amgen INC. | $231.07 | 2019-2023 | Otezla, Enbrel |
| Ucb, INC. | $223.18 | 2022-2024 | Bimzelx, Cimzia |
| Biofrontera INC. | $197.72 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Genentech USA, INC. | $190.48 | 2019-2020 | |
| Leo Pharma INC. | $140.50 | 2021-2024 | Adbry |
| Almirall LLC | $135.61 | 2019-2023 | Klisyri |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Strimling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.